Amgen's stem cell factor
Executive Summary
Phase I clinicals of the early acting hematopoietic growth factor will begin within "two to three weeks," Amgen Chief Financial Officer Lowell Sears reported Dec. 3 in New York. Addressing the Mabon Securities Research Conference, Sears said that SCF will be tested first in chemotherapy patients, but the firm expects that the recombinant protein's primary uses eventually will be for other conditions, such as bone marrow transplantation, radiation therapy and blood disorders.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: